Shenwei Pharmaceutical (02877.HK) had a first quarter revenue of 761 million yuan, a decrease of 31.9% year-on-year.

Tencent Finance APP news, Shineway Pharmaceutical (02877.HK) announced that as of March 31, 2025, the unaudited revenue from the management accounts for the three months reached 761 million yuan, a decrease of 31.9% compared to the same quarter of 2024. Specifically, the revenue of injection products decreased by 35.5% to 262 million yuan; the revenue of soft capsule products decreased by 52.9% to 81 million yuan; the revenue of granule products decreased by 41.2% to 117 million yuan; the revenue of traditional Chinese medicine formula granule products decreased by 13.8% to 244 million yuan; and the revenue of other dosage forms products decreased by 1.7% to 57 million yuan.